Allergy and Immunology Vol. I
Three topics, 44 cases — the volume's full planned scope. Choose one below to browse its cases.
Guideline-threshold combination therapy in allergic rhinitis, local and nonallergic rhinitis phenotypes, rhinitis medicamentosa, rhinitis in pregnancy, the unified-airway model, montelukast’s boxed warning, biologic-versus-revision-surgery thresholds in CRSwNP, macrolide therapy in chronic rhinosinusitis, allergic fungal sinusitis, AERD, acute rhinosinusitis, senile rhinitis, pediatric growth-suppression risk, allergic conjunctivitis, vernal keratoconjunctivitis, and SCIT-versus-SLIT immunotherapy selection
Atopic dermatitis management including JAK inhibitor selection with cardiovascular risk, reactive versus scheduled maintenance steroid therapy, infant facial eczema, refractory pediatric disease, and dupilumab dual-indication and add-on biologic decisions; allergic contact dermatitis; chronic spontaneous urticaria including antihistamine updosing, omalizumab escalation, and autoimmune-marker-guided therapy; cold urticaria; hereditary and ACE-inhibitor angioedema; and idiopathic angioedema without hives
Allergic-versus-eosinophilic biologic selection, ABPA and sub-threshold fungal sensitization (SAFS), occupational asthma, fibrotic hypersensitivity pneumonitis, EGPA with new organ involvement, dust-mite sublingual immunotherapy, omalizumab dosing-table edge cases, long-term omalizumab discontinuation and inter-biologic switching, discordant biomarker phenotypes, and omalizumab continuation through pregnancy